Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAF1 | P21675 | 4/20 | 1.00 |
| ▸ | BRD9 | Q9H8M2 | 5/20 | 0.76 |
| ▸ | BRD4 | O60885 | 13/20 | 0.59 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.56 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.56 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.56 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.56 |
| ▸ | EP300 | Q09472 | 1/20 | 0.56 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.56 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.56 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.56 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.56 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17748938 | 0.86 | BRD9 (1.00) | TAF1BRD9BRD4CECR2 | |
| SCHEMBL17748873 | 0.82 | TAF1 (1.00) | TAF1BRD9BRD4TRIM24SMARCA2 | |
| SCHEMBL17748894 | 0.76 | BRD4 (1.00) | TAF1BRD9BRD4TRIM24SMARCA2 | |
| SCHEMBL17748941 | 0.75 | BRD9 (1.00) | TAF1BRD9BRD4CECR2 | |
| SCHEMBL17748926 | 0.75 | BRD4 (1.00) | TAF1BRD9BRD4TRIM24SMARCA2 | |
| SCHEMBL17748871 | 0.74 | BRD4 (1.00) | TAF1BRD9BRD4TRIM24SMARCA2 | |
| SCHEMBL31590453 | 0.74 | BRD4 (0.66) | TAF1BRD9BRD4TRIM24SMARCA2 | |
| SCHEMBL17748905 | 0.73 | BRD4 (0.61) | TAF1BRD9BRD4TRIM24SMARCA2 | |
| SCHEMBL30306246 | 0.73 | BRD9 (0.74) | TAF1BRD9BRD4TRIM24SMARCA2 | |
| SCHEMBL17748918 | 0.72 | TAF1 (1.00) | TAF1BRD9BRD4TRIM24SMARCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3218374-B1 | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF BROMODOMAIN | GENENTECH INC (US) | 2021-12-29 | — | — | EP | claimed |
| CN-107108614-B | Substituted pyrrolopyridines as bromodomain inhibitors | 基因泰克公司 | 2021-06-01 | — | — | CN | claimed |
| US-10150767-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2018-12-11 | — | — | US | claimed |
| US-20170342067-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | claimed |
| EP-3218374-A1 | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF BROMODOMAIN | Genentech, Inc. (US) | 2017-09-20 | — | — | EP | claimed |
| WO-2016077380-A1 | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF BROMODOMAIN | GENENTECH, INC. (US) | 2016-05-19 | — | — | WO | claimed |
| EP-3218374-B1 | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF BROMODOMAIN | GENENTECH INC (US) | 2021-12-29 | — | — | EP | disclosed |
| CN-107108614-B | Substituted pyrrolopyridines as bromodomain inhibitors | 基因泰克公司 | 2021-06-01 | — | — | CN | disclosed |
| US-10150767-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2018-12-11 | — | — | US | disclosed |
| US-20170342067-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170342067-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| EP-3218374-A1 | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF BROMODOMAIN | Genentech, Inc. (US) | 2017-09-20 | — | — | EP | disclosed |
| WO-2016077380-A1 | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF BROMODOMAIN | GENENTECH, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342067-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRPF3 | TAF1 437/4885BRD9 12/4885BRD4 1/4885 |
| US-10150767-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRPF3 | TAF1 437/4885BRD9 12/4885BRD4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.